Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001021:Aortic Valve / Q000601:surgery; D001241:Aspirin / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001705:Bioprosthesis; D004176:Dipyridamole / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008943:Mitral Valve / Q000601:surgery*; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000188:drug therapy*; D013923:Thromboembolism / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D004176:Dipyridamole; D001241:Aspirin